MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03082nam a22003858i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
zzv350 b1853231 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20231102192126.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220523t20232023cau b 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2022023732 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0520388712 (paperback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780520388710 (paperback) |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
CU-S/DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| Modifying agency |
MiTN |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
HD9666.4 |
| Item number |
.R58 2023 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Roy, Victor, |
| Dates associated with a name |
1986- |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Capitalizing a cure : |
| Remainder of title |
how finance controls the price and value of medicines / |
| Statement of responsibility, etc. |
Victor Roy. |
| 263 ## - PROJECTED PUBLICATION DATE |
|---|
| Projected publication date |
2301. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Oakland, California : |
| Name of producer, publisher, distributor, manufacturer |
University of California Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2023] |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
A2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
pages cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent. |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Media type code |
n |
| Source |
rdamedia. |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Carrier type code |
nc |
| Source |
rdacarrier. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions ofpatients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and scienceand technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures"-- |
| Assigning source |
Provided by publisher. |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Gilead Sciences (Firm) |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug development |
| General subdivision |
Economic aspects |
| Geographic subdivision |
United States. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drugs |
| General subdivision |
Prices |
| Geographic subdivision |
United States. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hepatitis C |
| General subdivision |
Treatment |
| -- |
Prices |
| Geographic subdivision |
United States. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutical industry |
| General subdivision |
Economic aspects |
| Geographic subdivision |
United States. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Sofosbuvir |
| General subdivision |
Prices |
| Geographic subdivision |
United States. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Main entry heading |
Roy, Victor, 1986- |
| Title |
Capitalizing a cure |
| Place, publisher, and date of publication |
Oakland, California : University of California Press, [2023] |
| International Standard Book Number |
9780520388727 |
| Record control number |
(DLC) 2022023733. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Online version: |